BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses

British Journal of Cancer
E S PapadakisR I Cutress

Abstract

The co-chaperone protein Bcl-2-associated athanogene-1 (BAG-1) is overexpressed in breast cancer and has been incorporated in the oncotype DX and PAM50 breast cancer prognostic assays. Bcl-2-associated athanogene-1 exists as multiple protein isoforms that interact with diverse partners, including chaperones Hsc70/Hsp70, Ser/Thr kinase Raf-1 and Bcl-2, to promote cancer cell survival. The BAG-1L isoform specifically binds to and increases the transcriptional activity of oestrogen receptor in cells, and in some, but not all studies, BAG-1 expression is predictive of clinical outcome in breast cancer. A systematic review of published studies reporting BAG-1 (mRNA and/or protein) expression and clinical outcome in early breast cancer. The REporting Recommendations for Tumour MARKer and Prognostic Studies (REMARK) criteria were used as a template against which data were assessed. Meta-analyses were performed for studies that provided a hazard ratio and 95% confidence intervals for clinical outcomes including disease-free survival or breast cancer-specific survival from univariate analysis. Eighteen studies used differing methodologies and reported on differing outcomes. Meta-analyses were only possible on results from a subset of re...Continue Reading

References

Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S C TangN Shaheta
Mar 25, 2000·Endocrine-related Cancer·S KrajewskiJ C Reed
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B C TurnerJ C Reed
Mar 30, 2001·The Journal of Biological Chemistry·D A KneeJ C Reed
Oct 10, 2002·British Journal of Cancer·R I CutressG Packham
Dec 20, 2002·The New England Journal of Medicine·Marc J van de VijverRené Bernards
Aug 7, 2003·Oncogene·Ramsey I CutressGraham Packham
Dec 14, 2004·The New England Journal of Medicine·Soonmyung PaikNorman Wolmark
Apr 24, 2008·Breast Cancer Research : BCR·Yasmine NadlerYuval Kluger
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joel S ParkerPhilip S Bernard
Feb 27, 2009·Pathology, Research and Practice·Pauline AthanassiadouEfstratios Patsouris
Aug 20, 2009·The Journal of Pharmacology and Experimental Therapeutics·Adam SharpGraham Packham
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayDonald Maxwell Parkin
May 7, 2013·The Breast : Official Journal of the European Society of Mastology·Helen IngoldsbyGrace Callagy
Feb 22, 2014·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Hong LiuShou-Ching Tang
Nov 26, 2014·Nature Reviews. Clinical Oncology·Armand de GramontStanley R Hamilton
Jun 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mitch DowsettJack Cuzick

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies

Software Mentioned

OVID Online
STATA
Scopus
TAILORx

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

© 2022 Meta ULC. All rights reserved